Y·Axis Bio is the independent advisory practice of Greg Fralish, PhD. Twenty years of corporate and business development, corporate strategy, and capital raising across pharma and biotech — on both sides of the deal table, from startup to large-cap.
Corporate and business development inside large pharma and publicly traded biotechs: evaluating assets, structuring and executing licensing deals and acquisitions, running portfolio and partnering strategy, and leading strategic processes that transform and reshape organizations.
Leading the corporate strategy, corporate development, and business development functions — including alliance management: driving portfolio prioritization, incorporating external feedback from potential partners and KOL networks into strategic decisions, and running BD processes from first meeting through deal close and alliance establishment.
Grouped into four areas. Most engagements combine several.
Weighted scoring frameworks for ranking assets and BD opportunities — so teams allocate resources to what matters most.
Market sizing, competitive landscape, pricing analogues, and payer dynamics — built to hold up in partner and investor meetings.
Structured expert interviews to validate scientific and commercial assumptions before committing to a strategy or deal.
Deal NPV, scenario analysis, milestone structuring, and portfolio valuation — the quantitative backbone of every major decision.
Competitive positioning, portfolio strategy, M&A target identification, and board-level strategic advisory.
Deep-dive CI on pipeline activity, deal dynamics, and strategic positioning — actionable for senior leadership and boards.
Target identification, partner outreach strategy, and pipeline development — for both in-licensing and out-licensing mandates.
Scientific, commercial, and financial assessment of in-licensing or out-licensing opportunities — with modeling to back the view.
End-to-end BD process design — data room, CDA management, partner sequencing, and competitive tension management.
Deal economics design, milestone architecture, and royalty structuring — grounded in financial modeling and market comps.
Active negotiation support through term sheet to execution — with experience on both sides of the table informing every move.
Embedded BD function for companies that need senior leadership without a full-time hire — scalable up or down with your needs.
Matching your stage and story to the right capital instrument — institutional equity, non-dilutive, or hybrid approaches.
Series A/B process management, investor targeting, narrative development, and data room prep through close.
Strategy, writing support, and submission management for NIH, NSF, DoD, and other federal non-dilutive programs.
Identification and navigation of state economic development funds, life sciences-specific programs, and regional grants.
Early-stage investor targeting, pitch preparation, and process management for pre-institutional raises.
Capitalization modeling, use-of-proceeds planning, and valuation frameworks built for investor conversations.
Concept through incorporation — operating model, founding team strategy, IP structure, and early capital plan.
Foundational licensing from university technology transfer offices, asset in-licensing, spinout structuring, newco formation from academic or corporate IP, and venture creation from concept to capitalized.
Organizational structure, team formation, and operating rhythm design for early-stage and growth-stage companies.
Early product concepting and initial target product profile (TPP) development, shaped with external input from KOLs and prospective partners.
Scaling playbook development, BD function buildout, and strategic planning for companies moving from early to growth stage.
Independent board roles with operating depth — BD, strategy, and capital experience informing governance at every stage.
Six common engagement types. Select any to see detail.
I've spent 20+ years in corporate and business development — inside large pharma, publicly-traded and venture backed biotechs and as a founder and CEO building a company from the ground up.
Underpinning my work is a deep scientific and product development fluency. This allows me to connect the dots between strategy, organizational solves and the transactions that enable growth whether financing and/or partnering. I have worked seamlessly across therapeutic areas spanning oncology, immunology and inflammation, rare diseases with exposure to diverse modalities including small molecules, complex biologics, degraders, ai, cell therapy and beyond.
That work spans transactions on both sides of the table, capital raised across multiple sources, and hands-on company building — at organizations ranging from venture-backed startups to large pharma.
Y·Axis Bio is my independent practice. I named it Y-axis because I have always been motivated by curiosity and also because it is the Y-axis that is so critical to assessing the real meaning of data. Based in Greater Boston. Available for retained engagements, project work, and board advisory roles.
Portfolio prioritization · Commercial analysis · KOL engagement · Financial modeling
>$10B across dozens of deals — buy-side and sell-side licensing, collaborations, and acquisitions, plus classic corporate development moves including facility optimization and divestiture
>$150M across venture capital, state funds, angel and family office, and non-dilutive sources (SBIR, foundations)
GlycoEra · bluebird bio / 2seventy bio · Takeda · GlycoEra · Ziel Bio · UVA · Cato BioVentures
PhD, Biochemistry — University of Georgia · NIH NRSA Postdoctoral Fellow, Duke University
Tell me where things stand and what you're working on. I'll provide a direct assessment on whether I'm the right fit.
contact@yaxisbio.com linkedin.com/in/gregfralish